Affiliation:
1. I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia;
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Abstract
Recently, therapeutic options for treatment of chronic obstructive pulmonary disease (COPD) has been significantly extended, mainly due to new double and triple drug combinations in a single inhaler. Double combinations for treatment of COPD include long-term acting beta-2-agonists (LABA)/long-term acting muscarinic antagonists (LAMA) and LABA/inhaled corticosteroids (ICS); a triple combination is a combination of LABA, LAMA and ICS in a single inhaler. A review of consensus statements, national guidelines and recently published data about use of triple therapy in COPD, efficacy and safety of a triple combination is given in the article.
Publisher
Scientific and Practical Reviewed Journal Pulmonology
Subject
Pulmonary and Respiratory Medicine
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献